Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Mechanisms of SGLT2 Inhibition in Diabetic Kidney Disease
NCT06291155Phase 4Recruiting
- Sponsor
- University of Michigan
- Start
- Jan 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of canagliflozin in diabetic kidney disease (DKD), type 2 diabetes mellitus (T2DM), sponsored by University of Michigan. Started Jan 2024; status: recruiting.
02
Drugs
canagliflozin
03
Conditions
diabetic kidney disease (DKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06291155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06291155.